RespireRx Pharmaceuticals Inc (fka RSPI)

[DewDiligence]

>…all of the fund money that was in genentec, will have to be redistributed among the remaining bio's, as roche is not considered a bio, hence the need for redistribution.<

That’s an overstatement because DNA is owned by index funds and general large-cap funds, not just biotech funds. Clearly, there will be a significant money-flow benefit to other biotechs, but I would guess that less than 50% of the investor money in DNA will flow into other biotechs.